Pharmanutra S.p.A. (BIT:PHN)

Market Cap	826.34M +68.1%
Revenue (ttm)	138.73M +16.6%
Net Income	21.02M +28.1%
EPS	2.20 +28.8%
Shares Out	9.58M
PE Ratio	39.21
Forward PE	33.48
Dividend	1.20 (1.41%)
Ex-Dividend Date	May 4, 2026

Volume	9,006
Open	86.40
Previous Close	86.30
Day's Range	86.40 - 89.80
52-Week Range	38.75 - 91.20
Beta	0.10
Analysts	Strong Buy
Price Target	94.33 (+5.52%)
Earnings Date	May 28, 2026

About Pharmanutra

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for mu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 128
• Stock Exchange: Borsa Italiana
• Ticker Symbol: PHN

Financial Performance

In 2025, Pharmanutra's revenue was 132.16 million, an increase of 13.78% compared to the previous year's 116.15 million. Earnings were 20.00 million, an increase of 20.44%.